Today: Today, Bluebird Bio Inc. (BLUE) Receives Outperform Rating from Wedbush

Today, Bluebird Bio Inc. (BLUE) Receives Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note released on Wednesday morning. They currently have a $95.00 price target on the stock.

Several other analysts also recently commented on the company. Roth Capital initiated coverage on Bluebird Bio in a research note on Thursday, September 22nd. They set a buy rating and a $87.00 price objective on the stock. Goldman Sachs Group Inc. raised Bluebird Bio from a buy rating to a conviction-buy rating and set a $135.00 price objective on the stock in a research note on Thursday, September 15th. Cantor Fitzgerald downgraded Bluebird Bio from a hold rating to a sell rating and dropped their price objective for the stock from $65.24 to $37.00 in a research note on Friday, October 14th. Leerink Swann raised their price objective on Bluebird Bio from $67.00 to $80.00 and gave the stock an outperform rating in a research note on Friday, October 14th. Finally, Maxim Group reaffirmed a buy rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. Bluebird Bio currently has an average rating of Buy and an average target price of $82.82.

Shares of Bluebird Bio (NASDAQ:BLUE) opened at 60.65 on Wednesday. Bluebird Bio has a 12 month low of $35.37 and a 12 month high of $90.01. The firm’s market cap is $2.26 billion. The firm has a 50 day moving average price of $55.97 and a 200-day moving average price of $53.04.

Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.59) by $0.48. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.82 million. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.18) EPS. On average, analysts predict that Bluebird Bio will post ($7.05) EPS for the current fiscal year.

In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total transaction of $27,872.00. Following the completion of the sale, the insider now directly owns 5,891 shares in the company, valued at $394,697. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.50% of the company’s stock.

Large investors have recently modified their holdings of the company. First Mercantile Trust Co. bought a new stake in shares of Bluebird Bio during the third quarter valued at about $129,000. Sei Investments Co. increased its stake in shares of Bluebird Bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the company’s stock valued at $170,000 after buying an additional 1,298 shares during the period. Seven Eight Capital LLC bought a new stake in shares of Bluebird Bio during the first quarter valued at about $108,000. Winslow Evans & Crocker Inc. increased its stake in shares of Bluebird Bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the company’s stock valued at $183,000 after buying an additional 1,700 shares during the period. Finally, Advisor Group Inc. increased its stake in shares of Bluebird Bio by 482.2% in the third quarter. Advisor Group Inc. now owns 2,783 shares of the company’s stock valued at $188,000 after buying an additional 2,305 shares during the period.

Bluebird Bio Company Profile

Related posts

Leave a Comment